"In 2012, McKinsey published a report titled “Transforming India’s vaccine market” in association with the Organisation of Pharmaceutical Producers of India. The report suggests that India’s vaccine market is much smaller and underpenetrated than its global peers and discusses impediments that have hampered growth of the vaccine market. The report also features a scenario as per which the optimistic case would be that the market would have hit a value of around $3.2 billion in 2020, growing at 30-35% year-on-year from 2012 onwards. “In all likelihood, there will be five “mega” vaccines of over $250 million each in size, constituting 60% of the market, namely the anti-influenza, anti-typhoid, HPV, pneumococcal and Hepatitis A,” the report said."